DOI: https://doi.org/10.26641/2307-0404.2014.4.35805

Interrelation of blood lipid spectrum, level of systemic inflammation and mass of body in patients with coronary heart disease in combination with nonalcoholic fatty liver disease and their dynamics in terms of secondary prevention.

O. V. Kuryata, M. M. Grechanyk

Abstract


The article analyzes the blood lipid spectrum, level of systemic inflammation and their dynamics depending on body mass index in patients with coronary heart disease (CHD) in combination with nonalcoholic fatty liver disease (NAFLD) under the of influence statin therapy. 20 men (mean age 56,4±1,44 years) with CHD and NAFLD were examined. Levels of triglycerides (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP) were studied. 2 groups of patients according to BMI were distinguished: group 1 consisted of 9 (45%) patients who are overweight (BMI 25 to 30 kg/m2), group 2-8 (40%) with first degree of obesity (BMI 30 to 35). It was at found that at the initial state BMI increase at the range of 25-35 kg/m2 was not associated with a significant difference in the lipid spectrum, on the other hand on the background of treatment with pitavastatin in the dose of 2 mg for 8 weeks in patients with BMI of 25-30 kg/m2 more intensive reduction of TG (56.6%), LDL-C (31,8%), total cholesterol (22%), CRP (29.8%) and increased HDL-C (14,7%) was registered in contrast to the patients with BMI 30-35 kg/m2 – 33,7%, 22,8%, 8,8%, 10,1%, 11,9% respectively. Thus, in patients with CHD and NAFLD, pitavastatin in the dose of 2 mg has a moderate lipid-lowering effect, causes no significant increase in liver transaminases, which required dose adjustment or discontinuation of the drug.

Keywords


ischemic heart disease; nonalcoholic fatty liver disease; blood lipid spectrum; statins

Full Text:

PDF

References


Дзяк Г.В. Питавастатин – новый ингибитор ГМГ-КоА-редуктазы: особенности клинической фар¬ма¬ко¬логии и перспективы применения при лечении сердечно-сосудистых заболеваний / Г.В. Дзяк, К.Ю. Его¬ров, Э.Л. Колесник // Медичні перспективи. – 2013. – № 4. – С. 36–44.

Курята А.В. Влияние средних доз сим¬васта¬тина на липидный спектр крови, уровень системного воспаления в условиях вторичной профилактики ишемической болезни сердца / А.В. Курята, Н.И. Бар¬даченко // Ліки України.– 2013. – №9. – С. 76-79.

Курята О.В. Ліпідний обмін і кардіоваску¬лярний ризик у хворих на хронічну хворобу нирок: монографія / О.В. Курята, Є.О. Фролова. – Дніпро¬петровськ: Герда, 2013. – 112 с.

Реброва О.Ю. Статистический анализ меди¬цинских данных / О.Ю. Реброва. – М.: Медиасфера, 2006. – 305с.

Шевченко Л.М. Клініко-патогенетична ха¬рак¬те¬ристика неалкогольного стеатогепатиту в поєднанні з ішемічною хворобою серця у хворих молодого віку / Л.М. Шевченко, Л.М. Іванова // Сучасна гастроенте¬рологія. – 2009. – № 1 (45). – С. 14–17.

A Large-Scale Survey on Cardio-Cerebrovascular Events During pitavastatin (LIVALO Tablet) Therapy in Japanese patients with Hypercholesterolemia – LIVALO Ef¬fectiveness and Safety Study Extension (LIVES Study Ex¬tension) / T. Teramato, M. Urashima, H. Shimano [et al.] // Jаpаn. Pharmacol. Ther. – 2011. – Vol. 39. – P. 789-803.

De Alwis N.M. Non-alcoholic fatty liver disease: the mist gradually clears / N.M. de Alwis, C.P. Day // J. He¬patol. – 2008. – Vol. 48. – Р. 104–112.

Campeau L. Canadian Cardiovascular Society gra¬ding of angina pectoris revisited 30 years later / L. Campeau // Canadian J.Cardiology. – 2002. – Vol. 18, N 4. – P. 439-442.

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study // S. Bellentani, G. Pozzato [et al.] // 1999. – Vol. 44. – P. 874–880.

Effects of pravastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients / T. Molomura, M. Okamoto, N.Kitamura [et.al.] // J. Atheroscler. Thromb. – 2009. – Vol. 16. – Р. 546–552

ESC/EAS Guidelines for the management of dys¬lipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) // Eur. Heart J. – 2011. – Vol. 32. – P. 1769–1818.

High ratio of triglycerides to HDL-cholesterol ra¬tio predicts extensive coronary disease / P.L. da Luz, D. Fa¬varato, J.R. Faria-Neto [et al.]//Clinics. – 2008. – Vol. 63. – Р. 427–432

Prevalence of and risk factors for hepatic steatosis in Northern Italy / S. Belentani, G. Saccoccio, F. Masutti [et al.] // Ann. Intern. Med. – 2000. – Vol. 132. – Р. 112–117.

Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study / W. Dunn, R. Xu, D.L. Wingard [et al.] // Am. J. Gastro¬enterol. – 2008. –Vol. 103. – P. 2263–2271.

The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease / K. Mak, D. Bhatt [et al.] // Eur. Heart J. – 2009. – Vol. 30, N 7. – P. 857-865.

REFERENCES

Dzyak GV, Egorov KYu, Kolesnik EL. [Pitavastatin – a new inhibitor of the HMG-CoA reduc¬tase: peculiarities of clinical pharmacology and perspec¬tives of its usage in treatment of cardiovascular diseases]. Medichnі perspektivi. 2013;4:36–44. Ukraine.

Kuryata AV, Bardachenko NI. [The effects of mean dose of simvastatin on blood lipid spectrum, the level of systemic inflammation in the secondary preven¬tion of coronary heart disease. Lіki Ukraїni]. 2013;9:76–79. Ukraine.

Kuryata OV, Frolova EO. [Lipid metabolism and cardiovascular risk in patients with chronic kidney disease]. Dnipropetrovs'k: Gerda, 2013;112. Ukrainian.

Rebrova OYu. [Statistical analysis of medical data]. Media Sfera, 2006;305. Russian.

Shevchenko LM, Іvanova LM. [Clinical and pathogenetic characteristics of nonalcoholic steat¬ohepatitis in combination with coronary artery disease in young patients]. Suchasna gastroenterologija. 2009;1(45):14–17. Ukraine.

Teramato T, Urashima M, Shimano H [et al]. A Large-Scale Survey on Cardio-Cerebrovascular Events During pitavastatin (LIVALO Tablet) Therapy in Japane¬se patients with Hypercholesterolemia – LIVALO Ef¬fectiveness and Safety Study Extension (LIVES Study Extension). Jpn. Pharmacol. Ther. 2011;39:789–803.

De Alwis NM, Day CP. Non-alcoholic fatty liver di¬sease: the mist gradually clears. J. Hepatol. 2008;48:104–12.

Campeau L. Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Ca¬nadian J. Cardiology. 2002;18(4):439-42.

Bellentani S, Pozzato G. [et al]. Clinical course and risk factors of hepatitis C virus related liver disease in the ge¬ne¬ral population: report from the Dionysos study. 1999;44:874–80.

Molomura T, Okamoto M, Kitamura N. [et. al]. Effects of pravastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Athe¬roscler Thromb. 2009;16:546–52.

ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011;32:1769–818.

Da Luz PL, Favarato D, Faria-Neto JR. [at al]. High ratio of triglycerides to HDL-cholesterol ratio pre¬dicts extensive coronary disease. Clinics. 2008;63:427–32.

Belentani S, Saccoccio G, Masutti F. [et al]. Prevalence of and risk factors for hepatic steatosis in Nor¬thern Italy. Ann. Intern. Med. 2000;132:112–7.

Dunn W, Xu R, Wingard DL. [et al]. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study Am. J. Gastroenterol. 2008;103:2263–71.

Mak K, Bhatt D. The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. Eur. Heart J. 2009;30(7):857–65.


GOST Style Citations






 

This work is licensed under a Creative Commons Attribution 4.0 International License